Maxcyte (MXCT) Operating Leases (2020 - 2026)

Maxcyte (MXCT) has 7 years of Operating Leases data on file, last reported at $16.1 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 8.17% year-over-year to $16.1 million in Q1 2026; TTM through Mar 2026 was $16.1 million, a 8.17% decrease from a year earlier, with the FY2025 full-year figure at $16.5 million, down 3.98% from the prior year.
• Operating Leases for Q1 2026 stood at $16.1 million, down from $16.5 million in the prior quarter.
• Over the last five years, Operating Leases for MXCT reached as high as $18.0 million in Q4 2023 and fell as low as $12.8 million in Q1 2022.
• Historically, Operating Leases has averaged $16.3 million across 5 years, with a median of $16.5 million in 2025.
• Across the five-year window, Operating Leases surged 2873.17% in 2022 and retreated 8.17% in 2026, its largest moves.
• Year by year, Operating Leases stood at $15.9 million in 2022, then climbed by 12.74% to $18.0 million in 2023, then decreased by 4.45% to $17.2 million in 2024, then declined by 3.98% to $16.5 million in 2025, then declined by 2.27% to $16.1 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $16.1 million in Q1 2026, $16.5 million in Q4 2025, and $16.8 million in Q3 2025.